![]() |
首頁 > 美迪醫(yī)訊 > 聯(lián)合化療治療卵巢癌 |
聯(lián)合化療治療卵巢癌 【?2006-02-16 發(fā)布?】 美迪醫(yī)訊
研究人員將新近診斷的III期卵巢癌患者隨機分成兩組:接受靜脈化療,或者接受靜脈和腹腔內導管插入化療。 這項為期7年涉及400例患者的研究結果,發(fā)表在2006年1月5日《新英格蘭期刊》之上。 但是接受腹腔化療患者的副作用,包括血細胞計數(shù)減少和神經(jīng)系統(tǒng)疾病顯著增多,在治療期間的生活質量明顯較差。需要接受支持治療或者出現(xiàn)手術并發(fā)癥、腎功能不全、或者左側結腸切除的患者,都不適合腹腔內化療。205例入選患者之中只有86例能夠完成腹腔化療。 Combined Drug Method Best for Ovarian Cancer The investigators randomly grouped women with newly diagnosed stage III ovarian cancer into two categories: those who would get all chemotherapy intravenously or those who would get chemotherapy both intravenously and intraperitoneal (IP) through a catheter inserted directly into the abdomen. The results, from a seven-year study of more than 400 patients, were reported in the January 5, 2006, issue of The New England Journal of Medicine. However, side effects such as suppressed blood counts and neurologic problems were significantly worse for the group receiving abdominal chemotherapy, and they reported poorer quality of life during their treatment. Patients with adhesions or surgical complications, poor kidney function, and those who have had the left side of their colon removed during surgery are not good candidates for IP chemotherapy. Only 86 of the 205 patients enrolled for the abdominal therapy were able to complete the course. /**/本文關鍵字:
卵巢癌
《美迪醫(yī)訊》歡迎您參與新聞投稿,業(yè)務咨詢: 美迪醫(yī)療網(wǎng)業(yè)務咨詢更多關于 卵巢癌 的新聞
《上海醫(yī)療器械批發(fā)》產(chǎn)品推薦
|
合作支持:中華醫(yī)學會 | 中華醫(yī)院管理學會 | 國家食品藥品監(jiān)督管理家用護理器械商城 | 國藥勵展展覽有限責任公 | 醫(yī)學裝備協(xié)會 |
刊登廣告 | 友情鏈接 | 廣告代理商加盟 | 關于美迪 | 法律聲明 | 隱私保護 | 網(wǎng)站地圖 |
把美迪網(wǎng)放進收藏夾 把美迪醫(yī)療網(wǎng)介紹給我的朋友 給美迪醫(yī)療網(wǎng)留言
美迪醫(yī)療網(wǎng)廣告業(yè)務聯(lián)系:021-51601230 產(chǎn)品咨詢業(yè)務聯(lián)系:021-51601230 傳真:021-56532303 ![]() 互聯(lián)網(wǎng)藥品信息服務許可證:(滬)-經(jīng)營性-2009-0003 中華人民共和國電信與信息服務業(yè)務經(jīng)營許可證:(滬)B2-20090029 ![]() ![]() ![]() 公安備案號 31010602000199 醫(yī)療器械經(jīng)營許可證: 滬靜藥監(jiān)械經(jīng)營許20210003號 第二類醫(yī)療器械經(jīng)營備案憑證: 滬靜藥監(jiān)械經(jīng)營備20220042號 營業(yè)執(zhí)照:統(tǒng)一社會信用代碼91310108676284138X互聯(lián)網(wǎng)藥品信息服務資格書:(滬)-非經(jīng)營性-2023-0081 |